Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Halozyme Therapeutics, a biopharmaceutical company developing and commercialising products targeting the extracellular matrix for the drug delivery, endocrinology, oncology and dermatology markets, has reported revenues of $3.44m for the first quarter ended March 31, 2010, compared to $2.8m for the first quarter of 2009.
Subscribe to our email newsletter
Halozyme has posted a net loss of $11.8m for the first quarter 2010, or $ 0.13 per diluted share, compared to $14.7m, or $ 0.18 per diluted share, for the comparable period in 2009.
Operating loss was $11.8m, compared to $ 14.7m for the comparable period in 2009.
Jonathan Lim, president and CEO of Halozyme, said: “I am pleased with the progress that Halozyme and its alliance partners, Roche and Baxter, have achieved so far in 2010. The use of our rHuPH20 enzyme in these alliance programs will allow for subcutaneous administration that can potentially improve patient convenience, save healthcare resources, and, in the case of Herceptin SC, reduce the administration time to less than five minutes.”